Mechanisms of early death despite thrombolytic therapy: experience from the Thrombolysis in Myocardial Infarction Phase II (TIMI II) study.

[1]  H. Hellstrom.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. , 1991, Circulation.

[2]  W. Rogers,et al.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.

[3]  B. Rutherford,et al.  Results of primary angioplasty for acute myocardial infarction in patients with multivessel coronary artery disease. , 1990, Journal of the American College of Cardiology.

[4]  R. Califf,et al.  Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. , 1990, Circulation.

[5]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[6]  J. Gore,et al.  Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. , 1990, Circulation.

[7]  P. Morand,et al.  [Treatment of primary cardiogenic shock by coronary transluminal angioplasty during the acute phase of myocardial infarction]. , 1990, Archives des maladies du coeur et des vaisseaux.

[8]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[9]  E. Topol,et al.  Coronary angioplasty as primary therapy for acute myocardial infarction 6 to 48 hours after symptom onset: report of an initial experience. , 1989, Journal of the American College of Cardiology.

[10]  W. O’Neill,et al.  Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. , 1988, Circulation.

[11]  H. Sather,et al.  INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES Early Conclusions of Study CCG-106 by the Childrens Cancer Study Group , 1988, The Lancet.

[12]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[13]  T. Meinertz,et al.  The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. , 1988, The American journal of cardiology.

[14]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[15]  E. Braunwald,et al.  Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. , 1988, The American journal of cardiology.

[16]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[17]  E. B. Carlson,et al.  Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. , 1988, Circulation.

[18]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[19]  D. Rothbaum,et al.  Emergency percutaneous transluminal coronary angioplasty in acute myocardial infarction: a 3 year experience. , 1987, Journal of the American College of Cardiology.

[20]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[21]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[22]  M. Franzosi,et al.  [The Italian Group for the Study of Streptokinase in Myocardial Infarct: Analysis of intrahospital causes of death]. , 1987, Giornale italiano di cardiologia.

[23]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[24]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[25]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[26]  H. Morgenstern,et al.  Epidemiologic Research: Principles and Quantitative Methods. , 1983 .

[27]  B. Sobel,et al.  Progressive nature of myocardial injury in selected patients with cardiogenic shock. , 1978, The American journal of cardiology.

[28]  T. Waterston.  Fluids for diarrhoea in young children. , 1977, Lancet.

[29]  H. Galperin-Lemaître,et al.  ULTRASOUND AND SAFETY , 1976, The Lancet.

[30]  E. Veys,et al.  Letter: HL-A and infective sacroileitis. , 1974, Lancet.

[31]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[32]  T. Killip,et al.  Pathophysiology of Cardiogenic Shock: Quantification of Myocardial Necrosis, Clinical, Pathologic and Electrocardiographic Correlations , 1973, Circulation.

[33]  S. Gilder.  Home or Away. , 1964, Canadian Medical Association journal.

[34]  J. Sebus,et al.  THE SIMIAN CREASE. , 1964, Lancet.

[35]  Brain Wr,et al.  Mind and matter. , 1951 .